Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

The 2022 Tandem Meetings | Amphiregulin as a monitoring biomarker during treatment of acute GvHD

Shernan Holtan • 25 Apr 2022

The 2022 Tandem Meetings

General Human chorionic gonadotropin Ruxolitinib

REACH2

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, comments on the potential of amphiregulin as a biomarker to monitor patients during treatment of acute graft-versus-host disease (GvHD). Using samples collected from two prospective clinical trials, it was found that amphiregulin levels decreased in patients responding to treatment. This biomarker could be useful in clinical practice to monitor patients and determine whether a patient’s symptoms are related to GvHD or not. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting

Shernan Holtan • 10 Dec 2022

Unmet needs in GvHD & the promise of regenerative medicine

Shernan Holtan • 10 Dec 2022

How GvHD impacts patient quality of life

Shernan Holtan • 10 Dec 2022

ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC

Shernan Holtan • 10 Dec 2022

Related Videos

Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD

Florent Malard • 11 Apr 2024

The consequences of regulatory changes on access to devices and reagents needed for graft processing

Christian Chabannon • 16 Apr 2024

Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD

Mohamad Mohty • 17 Apr 2024

HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors

Rémy Duléry • 15 Apr 2024